Nuwellis, Inc. (NASDAQ:NUWE) is a medical device company that focuses on developing and commercializing products for fluid overload treatment. The company's primary product, the Aquadex SmartFlow system, is designed to remove excess fluid from patients suffering from heart failure and other conditions. Nuwellis operates in a competitive landscape with peers like Palisade Bio, NeuroBo Pharmaceuticals, Kiora Pharmaceuticals and First Wave BioPharma.
In evaluating Nuwellis, the Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC) are crucial metrics. Nuwellis has a ROIC of -177.98% and a WACC of 74.29%, resulting in a ROIC to WACC ratio of -2.40. This indicates that the company is not generating positive returns on its invested capital, as its returns are significantly below its cost of capital.
Comparing Nuwellis to its peers, Palisade Bio has a ROIC of -445.72% and a WACC of 9.99%, leading to a ROIC to WACC ratio of -44.62. NeuroBo Pharmaceuticals shows a ROIC of -206.48% and a WACC of 5.00%, with a ROIC to WACC ratio of -41.29. Both companies, like Nuwellis, are struggling to generate returns above their cost of capital.
Kiora Pharmaceuticals and First Wave BioPharma also face challenges. Kiora has a ROIC of -44.43% and a WACC of 4.92%, resulting in a ROIC to WACC ratio of -9.03. First Wave BioPharma's ROIC is -15.36% with a WACC of 7.76%, leading to a ROIC to WACC ratio of -1.98. These figures highlight the difficulties these companies face in generating returns on their invested capital.
